Medical Education

June 2012 View as a webpage | Forward to a colleague | Not subscribed? Subscribe here
Advances in Transplantation
Featured Articles

Updated guidelines on HCT graft selection

This article presents updated guidelines on the selection of unrelated donors and cord blood units for hematopoietic cell transplantation (HCT) developed by the NMDP and the CIBMTR (Center for International Blood and Marrow Transplant Research). The guidelines are based on large-scale studies correlating graft characteristics — primarily degree of donor-patient HLA match — with HCT outcomes. Other topics addressed include optimal timing of transplant, donor search strategies, and strategies to select the best partially matched unrelated donor or cord blood unit.

Spellman SR, et al. Blood »

Guidelines: HCT in autoimmune diseases

An update of the 1997 consensus guidelines for HCT in autoimmune diseases based on data reported to the European Group for Blood and Marrow Transplantation (EBMT). The guidelines discuss the use of HCT for treating autoimmune diseases in relation to the benefits, risks and health economic considerations of currently used non-transplant therapies. Patient safety and considerations for patient selection are also discussed.

Snowden JA, et al. Bone Marrow Transplant »

Comparing outcomes by age over time in HCT for AML

A multi-center comparison of outcomes of children (<15 years, n=900), adolescents and young adults (15-40 years, n=2,708) and older adults (>40 years, n=2,728) who underwent HCT for acute myeloid leukemia (AML). Outcomes were reported to the CIBMTR, and were analyzed over three time periods (1980-1988, 1989-1997, 1998-2005) for sibling donor transplants and two time periods (1989-1997, 1998-2005) for unrelated donor HCT. In a univariate analysis of sibling donor HCT, 5-year overall survival for all age groups improved significantly for patients transplanted 1998-2005 compared to those transplanted 1980-1988. Survival for unrelated donor HCT recipients also improved significantly over time (1989-1997 vs. 1998-2005).

Majhail NS, et al. Biol Blood Marrow Transplant »

Review: Chronic GVHD

A review discussing the challenges in diagnosing, understanding and treating chronic GVHD including the recently proposed National Institutes of Health consensus criteria for chronic GVHD. The authors note that the incidence and prevalence of chronic GVHD are growing, likely due to increased use of unrelated donors, peripheral blood rather than marrow grafts, decreased early transplant-related mortality, and increasing frequency of allogeneic HCT. Finally, the authors evaluate the possible role of immunomodulatory drugs thalidomide, lenalidomide and pomalidomide in preventing and treating chronic GVHD.

Linhares YPL, et al. Bone Marrow Transplant »

HCT for CLL in 20-year cohort

This single-institution study of 49 consecutive patients transplanted for chronic lymphocytic leukemia (CLL) between 1991-2009 found an overall survival (OS) of 63% at 2 years and 55% at 5 years and beyond. Donors were related (n=29) and unrelated (n=20) and conditioning regimens used were reduced-intensity (n=27) and myeloablative (n=22). Factors significantly predicting superior OS were comorbidity index <3, donor chimerism >90%, FISH rank (Dohner) and 17p deletion, pre-transplant alemtuzumab, complete remission post-transplant, post-transplant clearance of FISH abnormality, and absence of high-grade (III-IV) GVHD.

Toze CL, et al. Br J Haematol »

Review: HCT for myelofibrosis in the era of JAK inhibitors

A review focusing on the risks/benefits of JAK inhibitor therapy as compared to HCT in patients with myelofibrosis (MF). Although JAK1/2 inhibitors such as ruxolitinib can decrease the burden of MF-related constitutional symptoms, allogeneic HCT remains the only potentially curative therapy. The authors outline a risk-adapted approach individualized to each patient’s biologic characteristics and co-morbidities to determine optimal treatment strategies for patients with MF.

Gupta V, et al. Blood »

Test Your Knowledge

On average, how many potential donors join the NMDP Registry each month?

Answer Now
Other Noteworthy Articles
Prognostic factors for HCT outcomes in CML

Access abstract »

Mesenchymal stromal cells to prevent/treat GVHD

Access abstract »

Micafungin vs. itraconazole for fungal infections

Access abstract »

Resources For You
Last chance CME: Management of Advanced NHL

July 8 is the last day to access a free online CME activity, sponsored by the NMDP, focusing on four different disease subtypes of non-Hodgkin lymphoma where transplantation is an option for treatment. Access four-part CME »

Resources For Your Patients
Pediatric video wins awards
Super Sam Image

Our educational video for pediatric patients, Super Sam versus the Marrow Monsters, recently won a Gold Aster Award and two Silver Telly Awards, recognizing the exceptional quality of this resource. A special thanks to the remarkable patients, families and health care professionals who shared their experiences in this video. View Super Sam or order free copies »

Visit Us Online

Access outcomes data slides, CME, clinical references, patient education and more.

Go
 
Contact Us | Privacy Policy | Terms of Use | Unsubscribe | Vol. 12, No. 6  

Advances in Transplantation is an electronic newsletter published monthly by the National Marrow Donor Program (NMDP). This newsletter is sent only to those individuals who have requested to receive clinical education updates from NMDP.

If this e-mail message was forwarded to you and you'd like Advances in Transplantation delivered directly to you, please subscribe.

If you are a member of the NMDP Be The Match Registry®, unsubscribing to the Advances in Transplantation e-newsletter does not change your status on the registry. The NMDP may still contact you by e-mail, postal mail or telephone if a patient needs you or to request that you update your address.

National Marrow Donor Program, 3001 Broadway St. N.E., Minneapolis, MN 55413 | 1 (612) 627-5800 | Copyright © 2012